Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

TP53 Y220C Mutation: early-phase trial registry

1 of 1 indexed TP53 Y220C Mutation trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

TP53 Y220C Mutation: 1 US clinical trial tracked, 1 recruiting.

TP53 Y220C Mutation is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is PMV Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition tp53-y220c-mutation

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

TP53 Y220C Mutation (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near TP53 Y220C Mutation

TP53 Y220C Mutation lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for TP53 Y220C Mutation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. TP53 Y220C Mutation is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on TP53 Y220C Mutation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

midazolam hydrochloride syrup Drug
1 trials
repaglinide 0.5 mg tablet Drug
1 trials
rosuvastatin 10 mg tablet Drug
1 trials
metformin hydrochloride 500 mg tablet Drug
1 trials
rezatapopt Drug
1 trials

US sites by state

Facility locations filed on TP53 Y220C Mutation trials. A trial with sites in several states counts in each.

Texas 1 trials
Tennessee 1 trials
Florida 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this TP53 Y220C Mutation page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This TP53 Y220C Mutation condition card totals 1 registered trials; most-linked intervention midazolam hydrochloride syrup; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.